SFDA asks GSK to withdraw Augmentin syrup
The drug is indicated to treat a variety of infections in adults and children, in particular. With this move, China has become the latest Asia-Pacific nation, after Hong
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.